Anakinra Market Analysis: Key Insights on Growth Rates, Trends, and Major Opportunities
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the anakinra market grown in recent years?
The size of the anakinra market has experienced swift growth in the past few years. The market is projected to further expand from $4.89 billion in 2024 to $5.51 billion in 2025, with a compound annual growth rate (CAGR) of 12.8%. The surge noticed in the historic period is largely due to the rising occurrence of rheumatoid arthritis, the acceptance of anakinra for the treatment of rare autoinflammatory disorders such as NOMID, the increasing knowledge of biologics as a way to manage long-term inflammatory conditions, and the growing acceptance of targeted therapies.
How is the anakinra market size expected to evolve during the forecast period?
The market size of anakinra is projected to witness swift expansion in the coming years, eventually reaching a value of $8.81 billion in 2029, with a compound annual growth rate (CAGR) of 12.4%. This growth through the forecast period can be credited to the broader application of anakinra in multiple conditions, an increasing emphasis on personalised medicine, rising instances of rare autoinflammatory disorders, progression in drug delivery systems and improving healthcare accessibility in developing markets that is fuelling demand for biologics. Key trends during the forecast period include the production of biosimilars and innovative IL-1 inhibitors, the endorsement of home-based and self-administered treatments, partnerships between biotechnology firms and academic entities, and digital health strategies to bolster patient compliance.
Get your anakinra market report here!
https://www.thebusinessresearchcompany.com/report/anakinra-global-market-report
Which key drivers are propelling the anakinra market’s growth?
The escalating occurrence of autoimmune disorders is anticipated to drive the expansion of the anakinra market. Autoimmune disorders are health issues in which the body’s own immune system mistakenly attacks its own healthy tissues and organs, perceiving them as external threats. The increased prevalence of autoimmune disorders could be attributed to genetic predisposition and environmental factors like infections, pollution, and changes in diet, all of which contribute to the increased presence of these disorders. Anakinra serves as a treatment for autoimmune disorders by impeding the function of interleukin-1 (IL-1), reducing inflammation in conditions such as rheumatoid arthritis, Still’s disease, and periodic fever syndromes. For example, in June 2024, the Australian Institute of Health and Welfare, a governmental organization based in Australia, made public a report stating that in 2021–22, there were 10,000 hospitalizations for rheumatoid arthritis, marking a 25% increase from the preceding year’s 8,000. This adds up to a rate of 39 hospitalizations per 100,000 population. Therefore, the escalating occurrence of autoimmune disorders is stimulating the expansion of the anakinra market. The Impact of Surging Healthcare Expenditure on Market Growth
What are the market segments in the anakinra industry?
The anakinra market covered in this report is segmented –
1) By Indication: Rheumatoid Arthritis, Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still’s Disease, Neonatal-Onset Multisystem Inflammatory Disease, Other Indications
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Wholesale Pharmacies
3) By End-User: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Rheumatoid Arthritis: Moderate-to-Severe Disease, Early-stage Disease
2) By Cryopyrin-Associated Periodic Syndromes: Muckle-Wells Syndrome, Neonatal-Onset Multisystem Inflammatory Disease
3) By Familial Cold Autoinflammatory Syndrome: Acute Episodes, Chronic Symptoms
4) By Systemic Juvenile Idiopathic Arthritis: Active Systemic Disease, Inactive Disease With Flares
5) By Adult-Onset Still’s Disease: Active Disease, Remission Induction
6) By Neonatal-Onset Multisystem Inflammatory Disease: Acute Disease Episodes, Long-term Disease Management
7) By Other Indications: Gouty Arthritis, Osteoarthritis, Spondyloarthritis
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21095&type=smp
Which leading companies are shaping the growth of the anakinra market?
Major companies operating in the anakinra market are Swedish Orphan Biovitrum AB, Boehringer Ingelheim, Amgen Inc.
What key trends are currently impacting the anakinra market’s development?
Major firms in the Anakinra market are receiving regulatory clearances to broaden the scope for new therapeutic uses. Regulatory clearances are formal permissions granted by official government bodies, enabling a drug to be marketed and prescribed for certain health conditions, following an assessment of its safety, effectiveness, and quality. For example, in November 2022, the US-based Food and Drug Administration issued an Emergency Use Authorization (EUA) for Kineret (anakinra) to treat adults in hospital with pneumonia related to COVID-19 who needed additional oxygen. The objective was to minimize the chances of acute respiratory failure. The clearance was granted based on the outcomes of the SAVE-MORE phase 3 trial, which demonstrated that starting treatment early with Kineret enhanced patient results. Kineret functions by inhibiting cytokines IL-1a and IL-1ß, both of which contribute to the extreme inflammatory response seen in severe COVID-19 patients. Even though it doesn’t have full FDA authorization for this use, it’s permitted for temporary use throughout the public health crisis.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21095
Which geographic areas are influencing the growth of the anakinra market?
North America was the largest region in the anakinra market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anakinra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Chemotherapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report
Hormone Therapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report
Gastrointestinal Bleeding Treatment Devices Size Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
